SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-24-078585
Filing Date
2024-06-27
Accepted
2024-06-27 17:10:09
Documents
11
Period of Report
2024-06-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K tnya-20240625.htm   iXBRL 8-K 41569
  Complete submission text file 0000950170-24-078585.txt   158468

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tnya-20240625.xsd EX-101.SCH 25872
14 EXTRACTED XBRL INSTANCE DOCUMENT tnya-20240625_htm.xml XML 4909
Mailing Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080
Business Address 171 OYSTER POINT BLVD., SUITE 500 SOUTH SAN FRANCISCO CA 94080 415-865-2066
Tenaya Therapeutics, Inc. (Filer) CIK: 0001858848 (see all company filings)

IRS No.: 813789973 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40656 | Film No.: 241080325
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)